本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Dianthus Therapeutics Inc.

37.90
+2.336.55%
盘后35.00-2.9000-7.65%17:11 EDT
成交量:285.94万
成交额:1.04亿
市值:12.20亿
市盈率:-11.67
高:38.25
开:33.89
低:33.23
收:35.57
52周最高:38.25
52周最低:13.37
股本:3,218.83万
流通股本:1,345.91万
量比:1.52
换手率:21.25%
股息:- -
股息率:- -
每股收益(TTM):-3.2490
每股收益(LYR):-2.5506
净资产收益率:-34.71%
总资产收益率:-23.37%
市净率:4.03
市盈率(LYR):-14.86

数据加载中...

2024/10/07

SEC问询函

Form CORRESP - Correspondence
2024/09/16

重要事件披露

Form 8-K - Current report
2024/09/12

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/08/08

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/08/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/08

重要事件披露

Form 8-K - Current report
2024/06/06

重要事件披露

Form 8-K - Current report
2024/05/28

重要事件披露

Form 8-K - Current report
2024/05/09

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/09

重要事件披露

Form 8-K - Current report
2024/04/01

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/03/26

SEC问询函

Form CORRESP - Correspondence
2024/03/21

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/21

[修订]招股说明书

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2024/03/21

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/21

重要事件披露

Form 8-K - Current report
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/09

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]